Circulating tumor cells predict survival in patients with metastatic prostate cancer

To determine whether circulating tumor cells (CTCs) predict for survival in patients with metastatic prostate cancer (PCa) and to compare its prognostic abilities with other clinical factors. Blood samples from 37 patients with metastatic PCa were analyzed for CTCs. CTCs were enriched from 7.5 mL bl...

Full description

Saved in:

Bibliographic Details
Published in:	Urology (Ridgewood, N.J.) Vol. 65; no. 4; pp. 713 - 718
Main Authors:	Moreno, Jose G., Miller, M. Craig, Gross, Steve, Allard, W. Jeffrey, Gomella, Leonard G., Terstappen, Leon W.M.M.
Format:	Journal Article
Language:	English
Published:	New York, NY Elsevier Inc 01-04-2005 Elsevier Science
Subjects:	Aged Aged, 80 and over Biological and medical sciences Cell Count Gynecology. Andrology. Obstetrics Humans Male Male genital diseases Medical sciences Middle Aged Neoplastic Cells, Circulating - pathology Nephrology. Urinary tract diseases Prognosis Prostatic Neoplasms - mortality Prostatic Neoplasms - pathology Survival Rate Tumors Tumors of the urinary system Urinary tract. Prostate gland Human Nephrology Urinary system disease Prostate disease Patient Malignant tumor Metastasis Survival Urology Advanced stage Metastatic Predictive factor Male genital diseases Prostate cancer Tumor cell
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	To determine whether circulating tumor cells (CTCs) predict for survival in patients with metastatic prostate cancer (PCa) and to compare its prognostic abilities with other clinical factors. Blood samples from 37 patients with metastatic PCa were analyzed for CTCs. CTCs were enriched from 7.5 mL blood using magnetic nanoparticles targeting the epithelial cell adhesion molecule and then fluorescently labeled. The samples were analyzed by multiparameter flow cytometry, and events with appropriate light scatter properties that were nucleic acid dye positive, cytokeratin positive, and CD45 negative were defined as CTCs. The number of CTCs found ranged from 0 to 8586 per 7.5 mL (mean 530 ± 1887, median 5). A threshold of 5 or more CTCs per 7.5 mL of blood was used to evaluate the ability of CTCs to predict for overall survival. Of the 37 patients, 23 (62%) had 5 or more CTCs, with a median overall survival of 0.70 year compared with more than 4 years for those patients with fewer than 5 CTCs (log-rank P = 0.002, Cox hazards ratio 7.4). In the subset of 26 patients with hormone-refractory PCa, the presence of CTCs was the most significant parameter predictive of survival in univariate and multivariate analyses. In this pilot study, the presence of 5 or more CTCs in 7.5 mL blood was associated with poor overall survival in patients with metastatic PCa.
AbstractList	To determine whether circulating tumor cells (CTCs) predict for survival in patients with metastatic prostate cancer (PCa) and to compare its prognostic abilities with other clinical factors. Blood samples from 37 patients with metastatic PCa were analyzed for CTCs. CTCs were enriched from 7.5 mL blood using magnetic nanoparticles targeting the epithelial cell adhesion molecule and then fluorescently labeled. The samples were analyzed by multiparameter flow cytometry, and events with appropriate light scatter properties that were nucleic acid dye positive, cytokeratin positive, and CD45 negative were defined as CTCs. The number of CTCs found ranged from 0 to 8586 per 7.5 mL (mean 530 +/- 1887, median 5). A threshold of 5 or more CTCs per 7.5 mL of blood was used to evaluate the ability of CTCs to predict for overall survival. Of the 37 patients, 23 (62%) had 5 or more CTCs, with a median overall survival of 0.70 year compared with more than 4 years for those patients with fewer than 5 CTCs (log-rank P = 0.002, Cox hazards ratio 7.4). In the subset of 26 patients with hormone-refractory PCa, the presence of CTCs was the most significant parameter predictive of survival in univariate and multivariate analyses. In this pilot study, the presence of 5 or more CTCs in 7.5 mL blood was associated with poor overall survival in patients with metastatic PCa. OBJECTIVESTo determine whether circulating tumor cells (CTCs) predict for survival in patients with metastatic prostate cancer (PCa) and to compare its prognostic abilities with other clinical factors.METHODSBlood samples from 37 patients with metastatic PCa were analyzed for CTCs. CTCs were enriched from 7.5 mL blood using magnetic nanoparticles targeting the epithelial cell adhesion molecule and then fluorescently labeled. The samples were analyzed by multiparameter flow cytometry, and events with appropriate light scatter properties that were nucleic acid dye positive, cytokeratin positive, and CD45 negative were defined as CTCs.RESULTSThe number of CTCs found ranged from 0 to 8586 per 7.5 mL (mean 530 +/- 1887, median 5). A threshold of 5 or more CTCs per 7.5 mL of blood was used to evaluate the ability of CTCs to predict for overall survival. Of the 37 patients, 23 (62%) had 5 or more CTCs, with a median overall survival of 0.70 year compared with more than 4 years for those patients with fewer than 5 CTCs (log-rank P = 0.002, Cox hazards ratio 7.4). In the subset of 26 patients with hormone-refractory PCa, the presence of CTCs was the most significant parameter predictive of survival in univariate and multivariate analyses.CONCLUSIONSIn this pilot study, the presence of 5 or more CTCs in 7.5 mL blood was associated with poor overall survival in patients with metastatic PCa. To determine whether circulating tumor cells (CTCs) predict for survival in patients with metastatic prostate cancer (PCa) and to compare its prognostic abilities with other clinical factors. Blood samples from 37 patients with metastatic PCa were analyzed for CTCs. CTCs were enriched from 7.5 mL blood using magnetic nanoparticles targeting the epithelial cell adhesion molecule and then fluorescently labeled. The samples were analyzed by multiparameter flow cytometry, and events with appropriate light scatter properties that were nucleic acid dye positive, cytokeratin positive, and CD45 negative were defined as CTCs. The number of CTCs found ranged from 0 to 8586 per 7.5 mL (mean 530 ± 1887, median 5). A threshold of 5 or more CTCs per 7.5 mL of blood was used to evaluate the ability of CTCs to predict for overall survival. Of the 37 patients, 23 (62%) had 5 or more CTCs, with a median overall survival of 0.70 year compared with more than 4 years for those patients with fewer than 5 CTCs (log-rank P = 0.002, Cox hazards ratio 7.4). In the subset of 26 patients with hormone-refractory PCa, the presence of CTCs was the most significant parameter predictive of survival in univariate and multivariate analyses. In this pilot study, the presence of 5 or more CTCs in 7.5 mL blood was associated with poor overall survival in patients with metastatic PCa.
Author	Gomella, Leonard G. Miller, M. Craig Gross, Steve Allard, W. Jeffrey Terstappen, Leon W.M.M. Moreno, Jose G.
Author_xml	– sequence: 1 givenname: Jose G. surname: Moreno fullname: Moreno, Jose G. organization: Department of Urology, Thomas Jefferson University, Philadelphia, Pennsylvania – sequence: 2 givenname: M. Craig surname: Miller fullname: Miller, M. Craig organization: Immunicon Corporation, Huntingdon Valley, Pennsylvania – sequence: 3 givenname: Steve surname: Gross fullname: Gross, Steve organization: Immunicon Corporation, Huntingdon Valley, Pennsylvania – sequence: 4 givenname: W. Jeffrey surname: Allard fullname: Allard, W. Jeffrey organization: Immunicon Corporation, Huntingdon Valley, Pennsylvania – sequence: 5 givenname: Leonard G. surname: Gomella fullname: Gomella, Leonard G. organization: Department of Urology, Thomas Jefferson University, Philadelphia, Pennsylvania – sequence: 6 givenname: Leon W.M.M. surname: Terstappen fullname: Terstappen, Leon W.M.M. email: lterstappen@immunicon.com organization: Immunicon Corporation, Huntingdon Valley, Pennsylvania
BackLink	http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16724239$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/15833514$$D View this record in MEDLINE/PubMed
BookMark	eNqFkE1r3DAQhkXYkP1IfkKKLu3NjmRbknUqZekXBHpJz0IejxMt_thK8pb8-2pZwx570iCemXnn2ZLVOI1IyCNnOWdcPh3y2U_99PqeF4xVOec5Y_KGbLgoVKa1FiuyYUyzrCq0WJNtCAeWCCnVHVlzUZel4NWGvOydh7m30Y2vNM7D5Clg3wd69Ng6iDTM_uROtqdupMeE4RgD_eviGx0w2hDTFyR4OldIwY6A_p7cdrYP-LC8O_L729eX_Y_s-df3n_svzxmUuoxZgR00Das7UVvVtbqoG1vKgquu4dBorZCDRNGAsLpFUXEFqGwrteqERF6WO_LpMjft_zNjiGZw4RzfjjjNwUilqpqVMoHiAkIKGjx25ujdYP274cycdZqDWXSas07DuUmyUt-HZcHcDNheuxZ_Cfi4ADaA7Tuf7nfhyklVVEU6dkc-XzhMOk4OvQmQVEJy7BGiaSf3nyj_AJZ7mns
CODEN	URGYAZ
CitedBy_id	crossref_primary_10_1016_j_jpedsurg_2006_09_064 crossref_primary_10_1158_0008_5472_CAN_08_0630 crossref_primary_10_1007_s00432_013_1377_5 crossref_primary_10_1158_1078_0432_CCR_08_1910 crossref_primary_10_18632_oncotarget_6657 crossref_primary_10_1007_s10555_015_9597_6 crossref_primary_10_1158_1078_0432_CCR_08_1754 crossref_primary_10_1007_s12094_009_0421_z crossref_primary_10_1158_1078_0432_CCR_07_1506 crossref_primary_10_12954_PI_14056 crossref_primary_10_1158_0008_5472_CAN_08_2530 crossref_primary_10_1007_s00262_005_0072_z crossref_primary_10_1002_elps_202100318 crossref_primary_10_1039_c3lc00009e crossref_primary_10_1088_1361_6439_aa53ff crossref_primary_10_3390_cancers14184404 crossref_primary_10_1373_clinchem_2015_248260 crossref_primary_10_1634_theoncologist_2009_0094 crossref_primary_10_1158_1078_0432_CCR_10_3019 crossref_primary_10_2217_lmt_2017_0019 crossref_primary_10_1158_0008_5472_CAN_07_1687 crossref_primary_10_1155_2012_135281 crossref_primary_10_1016_j_bbadis_2009_02_012 crossref_primary_10_2217_fon_12_91 crossref_primary_10_1016_j_molmed_2006_01_006 crossref_primary_10_1007_s13277_014_1731_5 crossref_primary_10_1016_j_canlet_2008_12_007 crossref_primary_10_1016_j_trsl_2017_04_002 crossref_primary_10_1016_j_ejso_2011_01_025 crossref_primary_10_1371_journal_pone_0033788 crossref_primary_10_3892_ol_2017_6332 crossref_primary_10_1016_j_critrevonc_2011_05_004 crossref_primary_10_3390_ijms17091580 crossref_primary_10_1002_cncr_24350 crossref_primary_10_1016_j_critrevonc_2013_05_002 crossref_primary_10_1016_j_urology_2012_09_001 crossref_primary_10_1158_1078_0432_CCR_07_0268 crossref_primary_10_1371_journal_pone_0089474 crossref_primary_10_1158_1078_0432_CCR_06_2701 crossref_primary_10_1039_C7AN01979C crossref_primary_10_2144_fsoa_2019_0092 crossref_primary_10_3390_cancers12010127 crossref_primary_10_1002_pros_22845 crossref_primary_10_1007_s10555_019_09795_4 crossref_primary_10_1016_j_prnil_2019_01_003 crossref_primary_10_1115_1_4030420 crossref_primary_10_1016_j_euf_2019_05_008 crossref_primary_10_3748_wjg_v22_i46_10232 crossref_primary_10_1373_clinchem_2008_105601 crossref_primary_10_1586_14737159_2015_1011622 crossref_primary_10_1038_nrc2375 crossref_primary_10_1016_j_juro_2012_02_2558 crossref_primary_10_1093_annonc_mdq570 crossref_primary_10_1039_C3LC51107C crossref_primary_10_1200_JCO_2007_15_1472 crossref_primary_10_1158_0008_5472_CAN_08_0812 crossref_primary_10_1016_j_juro_2008_11_015 crossref_primary_10_1093_annonc_mdm533 crossref_primary_10_1038_s41571_020_00457_x crossref_primary_10_1053_j_seminoncol_2022_06_007 crossref_primary_10_2217_17520363_2_2_137 crossref_primary_10_1016_S1672_6529_08_60129_8 crossref_primary_10_3390_cancers11070933 crossref_primary_10_1016_j_snb_2013_02_065 crossref_primary_10_1186_1476_4598_9_174 crossref_primary_10_1111_j_1442_2042_2008_02224_x crossref_primary_10_1097_01_pdm_0000213463_98763_b9 crossref_primary_10_1038_nrurol_2012_136 crossref_primary_10_3389_fphot_2022_910035 crossref_primary_10_1016_j_lungcan_2012_04_005 crossref_primary_10_1158_1541_7786_MCR_16_0436 crossref_primary_10_1111_j_1464_410X_2007_06659_x crossref_primary_10_1016_j_eururo_2008_01_070 crossref_primary_10_1586_era_11_104 crossref_primary_10_3892_ol_2016_5432 crossref_primary_10_1109_TBCAS_2017_2764118 crossref_primary_10_3389_fonc_2020_601085 crossref_primary_10_1186_s13045_015_0174_9 crossref_primary_10_1038_sj_bjc_6604912 crossref_primary_10_1186_1471_2407_12_346 crossref_primary_10_1073_pnas_0813188106 crossref_primary_10_1002_cncr_29455 crossref_primary_10_3390_cancers12041011 crossref_primary_10_3390_ijms23041981 crossref_primary_10_1002_adma_201102151 crossref_primary_10_1002_smll_201403658 crossref_primary_10_1007_s10637_010_9420_8 crossref_primary_10_3390_cancers10110416 crossref_primary_10_1007_s10585_008_9157_3 crossref_primary_10_1111_j_1464_410X_2010_09562_x crossref_primary_10_1002_ijc_23717 crossref_primary_10_1073_pnas_1012539107 crossref_primary_10_3390_diagnostics5040428 crossref_primary_10_1083_jcb_202104108 crossref_primary_10_1097_MPA_0000000000000619 crossref_primary_10_1177_1758835920905415 crossref_primary_10_1111_iju_13505 crossref_primary_10_1016_j_suronc_2008_05_002 crossref_primary_10_1088_0034_4885_78_1_016601 crossref_primary_10_1093_annonc_mdq030 crossref_primary_10_1007_s10549_011_1603_2 crossref_primary_10_5858_2009_0022_CRR1_1 crossref_primary_10_1001_jamasurg_2023_5394 crossref_primary_10_1016_j_urolonc_2010_12_017 crossref_primary_10_1016_j_ejso_2008_12_003 crossref_primary_10_3390_genes6041053 crossref_primary_10_1016_j_mednuc_2007_11_006 crossref_primary_10_1186_s13046_018_0789_0 crossref_primary_10_1093_jnci_djk182 crossref_primary_10_1126_scitranslmed_3000403 crossref_primary_10_2217_fon_09_177 crossref_primary_10_1586_erm_10_35 crossref_primary_10_1016_j_clgc_2018_10_007 crossref_primary_10_1186_s12885_016_2886_9 crossref_primary_10_18632_oncotarget_3630 crossref_primary_10_1245_s10434_012_2417_0 crossref_primary_10_1158_1078_0432_CCR_08_0872 crossref_primary_10_1210_endocr_bqae022 crossref_primary_10_1093_annonc_mdm583 crossref_primary_10_1097_CCO_0000000000000655 crossref_primary_10_1158_1078_0432_CCR_07_1036 crossref_primary_10_1364_BOE_395289 crossref_primary_10_1155_2012_327104 crossref_primary_10_1093_annonc_mdl419 crossref_primary_10_1002_wnan_168 crossref_primary_10_1111_j_1442_2042_2010_02502_x crossref_primary_10_1186_s12918_018_0652_0 crossref_primary_10_1200_JCO_2013_51_7417 crossref_primary_10_14245_ns_1836140_070 crossref_primary_10_3390_ijms140918421 crossref_primary_10_1158_0008_5472_CAN_07_1657 crossref_primary_10_3892_ol_2013_1180 crossref_primary_10_1007_s10555_012_9389_1 crossref_primary_10_1111_j_1442_2042_2010_02454_x crossref_primary_10_1373_clinchem_2006_081828 crossref_primary_10_1177_1724600819849438 crossref_primary_10_1684_bdc_2012_1565 crossref_primary_10_1080_10408360600922632 crossref_primary_10_3390_jpm11040296 crossref_primary_10_2147_OTT_S285758 crossref_primary_10_1093_annonc_mdn544 crossref_primary_10_1200_PO_18_00352 crossref_primary_10_1002_ijc_29680 crossref_primary_10_1371_journal_pone_0149633 crossref_primary_10_1063_1_4939944 crossref_primary_10_1002_ijc_24953 crossref_primary_10_1007_s11934_006_0039_4 crossref_primary_10_1038_pcan_2009_25 crossref_primary_10_1371_journal_pone_0158354 crossref_primary_10_3892_ijo_2014_2409 crossref_primary_10_1007_s10544_011_9616_5 crossref_primary_10_1007_s00464_011_1773_3 crossref_primary_10_3892_ol_2016_5239 crossref_primary_10_1007_s11912_008_0022_y crossref_primary_10_1371_journal_pone_0121920 crossref_primary_10_1038_nrclinonc_2009_44 crossref_primary_10_1016_j_ucl_2011_07_001 crossref_primary_10_1007_s00432_011_0988_y crossref_primary_10_1177_1756287212453079 crossref_primary_10_1007_s40291_014_0101_8 crossref_primary_10_1016_j_juro_2008_06_021 crossref_primary_10_1053_j_gastro_2016_05_052 crossref_primary_10_1039_D2LC00443G crossref_primary_10_1309_AJCPH92SXYLIKKTS crossref_primary_10_3892_etm_2011_234 crossref_primary_10_1158_1541_7786_MCR_20_0975 crossref_primary_10_1039_b919820b
Cites_doi	10.1016/S1078-1439(03)00103-0 10.1016/j.urology.2003.10.026 10.1016/S0090-4295(01)01191-8 10.1200/JCO.1993.11.4.607 10.1016/j.urology.2003.10.013 10.1016/S0302-2838(02)00539-0 10.1016/j.urology.2003.11.016 10.1200/JCO.2003.04.104 10.1097/01.ju.0000129051.81608.d8 10.1200/JCO.1999.17.11.3461 10.1097/00005392-199909010-00034 10.1200/JCO.2003.06.100 10.1097/01.ju.0000094800.63501.15 10.1016/S0090-4295(97)00157-X 10.1001/jama.281.17.1591 10.1093/jnci/djg043 10.1002/1097-0142(20000615)88:12<2787::AID-CNCR18>3.0.CO;2-2 10.1056/NEJMoa040766 10.1373/clinchem.2003.028563
ContentType	Journal Article
Copyright	2005 Elsevier Inc. 2005 INIST-CNRS
Copyright_xml	– notice: 2005 Elsevier Inc. – notice: 2005 INIST-CNRS
DBID	IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8
DOI	10.1016/j.urology.2004.11.006
DatabaseName	Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1527-9995
EndPage	718
ExternalDocumentID	10_1016_j_urology_2004_11_006 15833514 16724239 S0090429504013421
Genre	Research Support, Non-U.S. Gov't Journal Article
GroupedDBID	--- --K --M -RU .1- .55 .FO .GJ .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 29Q 3O- 4.4 457 4CK 4G. 53G 5RE 5VS 6PF 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAEJM AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AAWTL AAXUO ABBQC ABFNM ABLJU ABLVK ABMAC ABMZM ABOCM ABXDB ABYKQ ACDAQ ACIUM ACRLP ACRZS ADBBV ADEZE ADMUD AEBSH AEKER AENEX AEVXI AFCTW AFFNX AFKWA AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AHHHB AHPSJ AIEXJ AIKHN AITUG AJBFU AJJEV AJOXV AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEA HMK HMO HVGLF HZ~ IHE J1W KOM L7B LCYCR LZ2 M29 M41 MO0 N9A O-L O9- OAUVE OK. OW. OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SAE SCC SDF SDG SDP SEL SES SPCBC SSH SSZ T5K UV1 WH7 WOW WUQ X7M XPP Z5R ZA5 ZGI ~G- 08R AAPBV AAUGY ABPIF ABPTK IQODW AAXKI AFJKZ AKRWK CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8
ID	FETCH-LOGICAL-c393t-2efcbb08f58a7fd928ba36217fb1cb997e1c6e5bc5a9de5417ce7ad697f56e133
ISSN	0090-4295
IngestDate	Fri Oct 25 05:54:10 EDT 2024 Thu Sep 26 15:52:50 EDT 2024 Sat Sep 28 07:45:35 EDT 2024 Sun Oct 22 16:06:41 EDT 2023 Fri Feb 23 02:11:22 EST 2024
IsPeerReviewed	true
IsScholarly	true
Issue	4
Keywords	Human Nephrology Urinary system disease Prostate disease Patient Malignant tumor Metastasis Survival Urology Advanced stage Metastatic Predictive factor Male genital diseases Prostate cancer Tumor cell
Language	English
License	CC BY 4.0
LinkModel	OpenURL
MergedId	FETCHMERGED-LOGICAL-c393t-2efcbb08f58a7fd928ba36217fb1cb997e1c6e5bc5a9de5417ce7ad697f56e133
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
PMID	15833514
PQID	67748036
PQPubID	23479
PageCount	6
ParticipantIDs	proquest_miscellaneous_67748036 crossref_primary_10_1016_j_urology_2004_11_006 pubmed_primary_15833514 pascalfrancis_primary_16724239 elsevier_sciencedirect_doi_10_1016_j_urology_2004_11_006
PublicationCentury	2000
PublicationDate	2005-04-01
PublicationDateYYYYMMDD	2005-04-01
PublicationDate_xml	– month: 04 year: 2005 text: 2005-04-01 day: 01
PublicationDecade	2000
PublicationPlace	New York, NY
PublicationPlace_xml	– name: New York, NY – name: United States
PublicationTitle	Urology (Ridgewood, N.J.)
PublicationTitleAlternate	Urology
PublicationYear	2005
Publisher	Elsevier Inc Elsevier Science
Publisher_xml	– name: Elsevier Inc – name: Elsevier Science
References	Kelly, Sher, Mazumdar (bib21) 1993; 11 Halabi, Small, Hayes (bib14) 2003; 21 Loberg, Fielhauer, Pienta (bib9) 2003; 62 O’Hara, Moreno, Zweitzig (bib23) 2004; 50 D’Amico, Moul, Carroll (bib8) 2003; 95 Halabi, Small, Kantoff (bib4) 2003; 21 Fehm, Sagalowsky, Clifford (bib20) 2002; 8 Schmid, Bernhard, Semjonow (bib12) 2000; 20 D’Amico, Cote, Loffredo (bib7) 2003; 170 Moreno, Croce, Fischer (bib13) 1992; 52 Ts’o, Pannek, Wang (bib15) 1997; 49 Bubley, Carducci, Dahut (bib3) 1999; 11 Cristofanilli, Budd, Ellis (bib19) 2004; 351 Schmid, Morant, Bernhard (bib11) 2003; 43 Wang, Eisenberger, Carducci (bib17) 2000; 88 Polascik, Wang, Shue (bib16) 1999; 162 Moreno, O’Hara, Gross (bib18) 2001; 58 Shulman, Benaim (bib5) 2004; 172 Crawford (bib1) 2003; 62 Shulman, Karam, Benaim (bib6) 2004; 63 Moul (bib10) 2003; 21 Pound, Partin, Eisenberger (bib2) 1999; 281 Hayes, Walker, Singh (bib22) 2002; 21 Moul (10.1016/j.urology.2004.11.006_bib10) 2003; 21 Loberg (10.1016/j.urology.2004.11.006_bib9) 2003; 62 Shulman (10.1016/j.urology.2004.11.006_bib6) 2004; 63 Hayes (10.1016/j.urology.2004.11.006_bib22) 2002; 21 Moreno (10.1016/j.urology.2004.11.006_bib18) 2001; 58 Fehm (10.1016/j.urology.2004.11.006_bib20) 2002; 8 Schmid (10.1016/j.urology.2004.11.006_bib11) 2003; 43 D’Amico (10.1016/j.urology.2004.11.006_bib8) 2003; 95 Halabi (10.1016/j.urology.2004.11.006_bib14) 2003; 21 Cristofanilli (10.1016/j.urology.2004.11.006_bib19) 2004; 351 Bubley (10.1016/j.urology.2004.11.006_bib3) 1999; 11 Ts’o (10.1016/j.urology.2004.11.006_bib15) 1997; 49 Polascik (10.1016/j.urology.2004.11.006_bib16) 1999; 162 Schmid (10.1016/j.urology.2004.11.006_bib12) 2000; 20 Wang (10.1016/j.urology.2004.11.006_bib17) 2000; 88 Moreno (10.1016/j.urology.2004.11.006_bib13) 1992; 52 Shulman (10.1016/j.urology.2004.11.006_bib5) 2004; 172 O’Hara (10.1016/j.urology.2004.11.006_bib23) 2004; 50 Halabi (10.1016/j.urology.2004.11.006_bib4) 2003; 21 Kelly (10.1016/j.urology.2004.11.006_bib21) 1993; 11 Crawford (10.1016/j.urology.2004.11.006_bib1) 2003; 62 Pound (10.1016/j.urology.2004.11.006_bib2) 1999; 281 D’Amico (10.1016/j.urology.2004.11.006_bib7) 2003; 170
References_xml	– volume: 52 start-page: 6110 year: 1992 end-page: 6112 ident: bib13 article-title: Detection of hematogenous micrometastasis in patients with prostate cancer publication-title: Cancer Res contributor: fullname: Fischer – volume: 95 start-page: 1376 year: 2003 end-page: 1383 ident: bib8 article-title: Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy publication-title: J Natl Cancer Inst contributor: fullname: Carroll – volume: 11 start-page: 3461 year: 1999 end-page: 3467 ident: bib3 article-title: Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer publication-title: J Clin Oncol contributor: fullname: Dahut – volume: 8 start-page: 2073 year: 2002 end-page: 2084 ident: bib20 article-title: Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant publication-title: Clin Cancer Res contributor: fullname: Clifford – volume: 351 start-page: 781 year: 2004 end-page: 791 ident: bib19 article-title: Circulating tumor cells, disease progression and survival in metastatic breast cancer publication-title: N Engl J Med contributor: fullname: Ellis – volume: 62 start-page: 128 year: 2003 end-page: 133 ident: bib9 article-title: Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer publication-title: Urology contributor: fullname: Pienta – volume: 170 start-page: S42 year: 2003 end-page: S47 ident: bib7 article-title: Determinants of prostate cancer specific survival following radiation therapy during the prostate specific antigen era publication-title: J Urol contributor: fullname: Loffredo – volume: 58 start-page: 386 year: 2001 end-page: 392 ident: bib18 article-title: Changes in circulating carcinoma cells in metastatic prostate cancer patients correlates with disease status publication-title: Urology contributor: fullname: Gross – volume: 21 start-page: 1111 year: 2002 end-page: 1118 ident: bib22 article-title: Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer publication-title: Int J Oncol contributor: fullname: Singh – volume: 62 start-page: 3 year: 2003 end-page: 12 ident: bib1 article-title: Epidemiology of prostate cancer publication-title: Urology contributor: fullname: Crawford – volume: 49 start-page: 881 year: 1997 end-page: 885 ident: bib15 article-title: Detection of intact prostate cancer cells in the blood of men with prostate cancer publication-title: Urology contributor: fullname: Wang – volume: 162 start-page: 749 year: 1999 end-page: 752 ident: bib16 article-title: Influence of sextant prostate needle biopsy or surgery on the detection and harvest of intact circulating prostate cancer cells publication-title: J Urol contributor: fullname: Shue – volume: 11 start-page: 607 year: 1993 end-page: 615 ident: bib21 article-title: Prostate-specific antigen as measure of disease outcome in metastatic hormone refractory prostate cancer publication-title: J Clin Oncol contributor: fullname: Mazumdar – volume: 43 start-page: 28 year: 2003 end-page: 30 ident: bib11 article-title: Prostate specific antigen doubling time as auxiliary end point in hormone refractory prostatic carcinoma publication-title: Eur Urol contributor: fullname: Bernhard – volume: 21 start-page: 1232 year: 2003 end-page: 1237 ident: bib4 article-title: Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer publication-title: J Clin Oncol contributor: fullname: Kantoff – volume: 50 start-page: 826 year: 2004 end-page: 835 ident: bib23 article-title: Multigene reverse transcription-PCR profiling of circulating tumor cells in hormone-refractory prostate cancer publication-title: Clin Chem contributor: fullname: Zweitzig – volume: 63 start-page: 732 year: 2004 end-page: 736 ident: bib6 article-title: Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer publication-title: Urology contributor: fullname: Benaim – volume: 21 start-page: 292 year: 2003 end-page: 304 ident: bib10 article-title: Variables in predicting survival based on treating “PSA-only” relapse publication-title: Urol Oncol contributor: fullname: Moul – volume: 172 start-page: 141 year: 2004 end-page: 145 ident: bib5 article-title: The natural history of androgen independent prostate cancer publication-title: J Urol contributor: fullname: Benaim – volume: 88 start-page: 2787 year: 2000 end-page: 2795 ident: bib17 article-title: Identification and characterization of circulating prostate carcinoma cells publication-title: Cancer contributor: fullname: Carducci – volume: 20 start-page: 4985 year: 2000 end-page: 4987 ident: bib12 article-title: Prostate specific antigen in as a dynamic model in advanced prostate cancer publication-title: Anticancer Res contributor: fullname: Semjonow – volume: 21 start-page: 490 year: 2003 end-page: 495 ident: bib14 article-title: Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer publication-title: J Clin Oncol contributor: fullname: Hayes – volume: 281 start-page: 1591 year: 1999 end-page: 1597 ident: bib2 article-title: Natural history of progression to metastases and death from prostate cancer in men with PSA recurrence following radical prostatectomy publication-title: JAMA contributor: fullname: Eisenberger – volume: 21 start-page: 292 year: 2003 ident: 10.1016/j.urology.2004.11.006_bib10 article-title: Variables in predicting survival based on treating “PSA-only” relapse publication-title: Urol Oncol doi: 10.1016/S1078-1439(03)00103-0 contributor: fullname: Moul – volume: 62 start-page: 128 issue: suppl 1 year: 2003 ident: 10.1016/j.urology.2004.11.006_bib9 article-title: Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer publication-title: Urology doi: 10.1016/j.urology.2003.10.026 contributor: fullname: Loberg – volume: 21 start-page: 1111 year: 2002 ident: 10.1016/j.urology.2004.11.006_bib22 article-title: Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer publication-title: Int J Oncol contributor: fullname: Hayes – volume: 58 start-page: 386 year: 2001 ident: 10.1016/j.urology.2004.11.006_bib18 article-title: Changes in circulating carcinoma cells in metastatic prostate cancer patients correlates with disease status publication-title: Urology doi: 10.1016/S0090-4295(01)01191-8 contributor: fullname: Moreno – volume: 11 start-page: 607 year: 1993 ident: 10.1016/j.urology.2004.11.006_bib21 article-title: Prostate-specific antigen as measure of disease outcome in metastatic hormone refractory prostate cancer publication-title: J Clin Oncol doi: 10.1200/JCO.1993.11.4.607 contributor: fullname: Kelly – volume: 62 start-page: 3 year: 2003 ident: 10.1016/j.urology.2004.11.006_bib1 article-title: Epidemiology of prostate cancer publication-title: Urology doi: 10.1016/j.urology.2003.10.013 contributor: fullname: Crawford – volume: 43 start-page: 28 year: 2003 ident: 10.1016/j.urology.2004.11.006_bib11 article-title: Prostate specific antigen doubling time as auxiliary end point in hormone refractory prostatic carcinoma publication-title: Eur Urol doi: 10.1016/S0302-2838(02)00539-0 contributor: fullname: Schmid – volume: 63 start-page: 732 year: 2004 ident: 10.1016/j.urology.2004.11.006_bib6 article-title: Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer publication-title: Urology doi: 10.1016/j.urology.2003.11.016 contributor: fullname: Shulman – volume: 21 start-page: 490 year: 2003 ident: 10.1016/j.urology.2004.11.006_bib14 article-title: Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2003.04.104 contributor: fullname: Halabi – volume: 172 start-page: 141 year: 2004 ident: 10.1016/j.urology.2004.11.006_bib5 article-title: The natural history of androgen independent prostate cancer publication-title: J Urol doi: 10.1097/01.ju.0000129051.81608.d8 contributor: fullname: Shulman – volume: 8 start-page: 2073 year: 2002 ident: 10.1016/j.urology.2004.11.006_bib20 article-title: Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant publication-title: Clin Cancer Res contributor: fullname: Fehm – volume: 20 start-page: 4985 year: 2000 ident: 10.1016/j.urology.2004.11.006_bib12 article-title: Prostate specific antigen in as a dynamic model in advanced prostate cancer publication-title: Anticancer Res contributor: fullname: Schmid – volume: 11 start-page: 3461 year: 1999 ident: 10.1016/j.urology.2004.11.006_bib3 article-title: Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer publication-title: J Clin Oncol doi: 10.1200/JCO.1999.17.11.3461 contributor: fullname: Bubley – volume: 162 start-page: 749 year: 1999 ident: 10.1016/j.urology.2004.11.006_bib16 article-title: Influence of sextant prostate needle biopsy or surgery on the detection and harvest of intact circulating prostate cancer cells publication-title: J Urol doi: 10.1097/00005392-199909010-00034 contributor: fullname: Polascik – volume: 21 start-page: 1232 year: 2003 ident: 10.1016/j.urology.2004.11.006_bib4 article-title: Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2003.06.100 contributor: fullname: Halabi – volume: 170 start-page: S42 year: 2003 ident: 10.1016/j.urology.2004.11.006_bib7 article-title: Determinants of prostate cancer specific survival following radiation therapy during the prostate specific antigen era publication-title: J Urol doi: 10.1097/01.ju.0000094800.63501.15 contributor: fullname: D’Amico – volume: 49 start-page: 881 year: 1997 ident: 10.1016/j.urology.2004.11.006_bib15 article-title: Detection of intact prostate cancer cells in the blood of men with prostate cancer publication-title: Urology doi: 10.1016/S0090-4295(97)00157-X contributor: fullname: Ts’o – volume: 281 start-page: 1591 year: 1999 ident: 10.1016/j.urology.2004.11.006_bib2 article-title: Natural history of progression to metastases and death from prostate cancer in men with PSA recurrence following radical prostatectomy publication-title: JAMA doi: 10.1001/jama.281.17.1591 contributor: fullname: Pound – volume: 95 start-page: 1376 year: 2003 ident: 10.1016/j.urology.2004.11.006_bib8 article-title: Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djg043 contributor: fullname: D’Amico – volume: 88 start-page: 2787 year: 2000 ident: 10.1016/j.urology.2004.11.006_bib17 article-title: Identification and characterization of circulating prostate carcinoma cells publication-title: Cancer doi: 10.1002/1097-0142(20000615)88:12<2787::AID-CNCR18>3.0.CO;2-2 contributor: fullname: Wang – volume: 52 start-page: 6110 year: 1992 ident: 10.1016/j.urology.2004.11.006_bib13 article-title: Detection of hematogenous micrometastasis in patients with prostate cancer publication-title: Cancer Res contributor: fullname: Moreno – volume: 351 start-page: 781 year: 2004 ident: 10.1016/j.urology.2004.11.006_bib19 article-title: Circulating tumor cells, disease progression and survival in metastatic breast cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa040766 contributor: fullname: Cristofanilli – volume: 50 start-page: 826 year: 2004 ident: 10.1016/j.urology.2004.11.006_bib23 article-title: Multigene reverse transcription-PCR profiling of circulating tumor cells in hormone-refractory prostate cancer publication-title: Clin Chem doi: 10.1373/clinchem.2003.028563 contributor: fullname: O’Hara
SSID	ssj0006667
Score	2.3139007
Snippet	To determine whether circulating tumor cells (CTCs) predict for survival in patients with metastatic prostate cancer (PCa) and to compare its prognostic... OBJECTIVESTo determine whether circulating tumor cells (CTCs) predict for survival in patients with metastatic prostate cancer (PCa) and to compare its...
SourceID	proquest crossref pubmed pascalfrancis elsevier
SourceType	Aggregation Database Index Database Publisher
StartPage	713
SubjectTerms	Aged Aged, 80 and over Biological and medical sciences Cell Count Gynecology. Andrology. Obstetrics Humans Male Male genital diseases Medical sciences Middle Aged Neoplastic Cells, Circulating - pathology Nephrology. Urinary tract diseases Prognosis Prostatic Neoplasms - mortality Prostatic Neoplasms - pathology Survival Rate Tumors Tumors of the urinary system Urinary tract. Prostate gland
Title	Circulating tumor cells predict survival in patients with metastatic prostate cancer
URI	https://dx.doi.org/10.1016/j.urology.2004.11.006 https://www.ncbi.nlm.nih.gov/pubmed/15833514 https://search.proquest.com/docview/67748036
Volume	65
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
link	http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Jb9NAFB6FVkJICLETljIHbpGNHS_jOVYhUCqll6aiN2s8M0auVLuyY34_bzbbASoWiYsVTTTx5L3Pb_NbEHpHqeCBKCMvEAH3Ys5SD5Re4VEu0pBFlJe6ievJOTm7zD6s4_Vs5qaWjWv_ldOwBrxWlbN_we3hR2EBPgPP4Qpch-sf8X1VtVyP5FJlUP110y5UbL5TzQBExXeLrgfh8E232nBNVW2F27XcMVVfVHGVtaUrjVROGLf5u9aCvWhN1yYVelC1Xi5n58w_9SdhhU3Tyrpx7xgWn_zhi6H4cOMvVi2rvo4pQHaCu560NiARcGrS77_4ru5sL1SRTDJcdPzM1dDspXiCkRd4oBXNu21pxfCSeGC6JlM5bWZKWDzGE6FLTDWr1d_EyPOfVIOJUlz5vSGTDg34qoFr8EMrbq3cz9Wx1KkC5YDGqlXB4RJkGYjSw-PP68vTQd2D_2cbs5q_MZaJvf_lzW4zgO7fsA4ey9LMU7nd4dGGz_YhemA9FnxsoPYIzWT9GN3d2JyMJ2g7QRzWiMMacdgiDjvE4arGDnFYIQ6PiMMOcdgg7im6-Ljerk48O6vD4xGNdt5SlrwogqxMMkZKQZdZwcA2CklZhLyglMiQpzIpeMKokEkcEi4JEyklZZLKMIqeoYO6qeULhIlMVIcmsOwDFsPuLGQSNEsW8UKUYZrNke8ImN-Yliy5y1W8yi3F1XjVGNzbHCg-R5kjc27tSmMv5oCN32092mPLeMOUKE-EztFbx6ccBLOiL6tl03d5Co5VBvbhHD037Bv36krHMH757-d6he6ND9hrdLBre_kG3elEf2Tx-R3rxL1_
link.rule.ids	315,782,786,27933,27934
linkProvider	Elsevier
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Circulating+tumor+cells+predict+survival+in+patients+with+metastatic+prostate+cancer&rft.jtitle=Urology+%28Ridgewood%2C+N.J.%29&rft.au=Moreno%2C+Jose+G.&rft.au=Miller%2C+M.+Craig&rft.au=Gross%2C+Steve&rft.au=Allard%2C+W.+Jeffrey&rft.date=2005-04-01&rft.pub=Elsevier+Inc&rft.issn=0090-4295&rft.eissn=1527-9995&rft.volume=65&rft.issue=4&rft.spage=713&rft.epage=718&rft_id=info:doi/10.1016%2Fj.urology.2004.11.006&rft.externalDocID=S0090429504013421
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0090-4295&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0090-4295&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0090-4295&client=summon